Trinity Meds GLP-1 Advertorial 2026: Compounded Semaglutide From $159, Tirzepatide From $259, FDA June 29 Deadline, and What to Know Before Enrolling

ALPHARETTA, Ga., May 5, 2026 (Newswire.com) - Advertorial Disclosure: This article contains affiliate links. If you purchase through these links, a commission may be earned at no additional cost to you. This content is for informational purposes only and does not constitute medical advice, diagnosis, treatment, legal advice, or regulatory guidance. Prescription decisions are made by licensed clinicians, eligibility is not guaranteed, and compounded GLP-1 medications referenced in this article are not FDA-approved finished products and have not been individually reviewed by FDA for safety, effectiveness, or quality.

Trinity Meds GLP-1 2026: Compounded Semaglutide From $159, Tirzepatide From $259, FDA's April 2026 Proposal, and Key Consumer Considerations Before the June 29 Comment Deadline

The FDA's public comment period on proposed restrictions affecting compounded semaglutide and tirzepatide closes June 29, 2026. For patients currently researching Trinity Meds and similar telehealth programs, that deadline frames a question worth answering now: what does the program actually disclose, what does the 2026 regulatory environment mean for compounded GLP-1 access, and what should any prospective patient understand before enrolling? This advertorial covers all of it - pricing, program structure, FDA context, pharmacy partners, and the consumer terms worth reading before any decision is made.

The regulatory backdrop matters here. The FDA resolved the semaglutide shortage in February 2025 and the tirzepatide shortage in late 2024. Then, on April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list entirely - citing no clinical need for outsourcing facilities to compound these drugs from bulk substances. Compounded GLP-1 programs that were routine in 2023 are now operating under a materially different regulatory environment, and the window for public comment on that proposed change closes in weeks, not months.

Trinity Meds is one of the self-pay telehealth platforms that continues to appear in this conversation. Its published materials list compounded semaglutide starting at $159 per month, compounded tirzepatide starting at $259 per month, a telehealth intake process, clinician review, and four named dispensing pharmacies. This advertorial summarizes what the brand's published materials disclose about the program's structure, pricing, FDA status, pharmacy partners, eligibility criteria, and consumer terms - presented in one place so readers can make their own fully informed decision.

Nothing in this article constitutes medical advice, legal guidance, or a recommendation to choose any specific medication or program. Readers should consult a licensed healthcare professional before starting any prescription weight-management treatment.

View the current Trinity Meds offer summary

What Trinity Meds' Published Materials Say the Platform Is

According to Trinity Meds' published terms, the platform - operating as Trinity Healthcare Supply, LLC, and also under the brand name CareGLP, owned by Trinity Meds, Inc. - functions as a service that facilitates intake, administrative support, payment coordination, telehealth communications, and optional prescription fulfillment coordination. Published contact information lists an Alpharetta, Georgia address and a Tampa, Florida mailing address.

The terms state that the platform does not directly provide medical or pharmacy services, does not control independent medical providers, and does not manufacture, dispense, or control the formulation of medications prescribed through the service. This separation - platform, prescribing clinicians, and dispensing pharmacies as three distinct entities - is a relevant transparency point for prospective patients reviewing how the brand describes its structure and the respective roles of each party involved in the program.

Trinity Meds, CareGLP, Medical Providers, and Pharmacy Role Separation

Per the company's published terms and website disclosures, three distinct entities are involved in the Trinity Meds program:

• The platform - Trinity Meds / CareGLP, operated by Trinity Healthcare Supply, LLC. Per published terms, this entity facilitates intake, communications, administrative coordination, and logistics. It does not practice medicine, prescribe medication, compound, manufacture, or dispense.

• The medical group - CareValidate Health. According to the company's published terms, CareValidate Health is a network of US-licensed clinicians operating through affiliated professional entities. A CareValidate Health clinician reviews intake information and makes the independent prescribing decision. Per the terms, completing the online assessment and submitting payment does not establish a doctor-patient relationship and does not guarantee a prescription - that decision rests entirely with the licensed clinician based on independent medical judgment.

• The dispensing pharmacies. According to the company's published FAQ, Trinity Meds names four pharmacy partners for prescription fulfillment: Belmar Pharmacy, Strive Pharmacy, Epiq Scripts, and Casa Pharma Rx. Published terms state that Trinity Meds does not produce compounded medications, and that patients may receive medication that looks different from marketing materials because compounded preparations are produced independently by each pharmacy under their own state licensure and quality controls.

Trinity Meds' website lists clinicians including Dr. David Mansour, Dr. Kelly Tenbrink, and Dr. Ana Lisa Carr, with credentials displayed by the brand. Prospective patients should verify clinician licensure, state eligibility, and clinical credentials directly through the applicable state licensing board or with the assigned provider before beginning treatment.

View the current Trinity Meds offer summary

Published Pricing: Semaglutide From $159, Tirzepatide From $259, Ozempic From $999

According to Trinity Meds' published website materials, the platform lists the following published starting pricing:

• Compounded semaglutide: from $159 per month. Once-weekly subcutaneous injection. Trinity Meds' published materials describe compounded semaglutide in relation to the active ingredient used in Wegovy and Ozempic; however, compounded semaglutide is not Wegovy, Ozempic, a generic version, or an FDA-approved finished product.

• Compounded tirzepatide: from $259 per month. Once-weekly subcutaneous injection. Trinity Meds' published materials describe compounded tirzepatide in relation to the active ingredient used in Mounjaro and Zepbound; however, compounded tirzepatide is not Mounjaro, Zepbound, a generic version, or an FDA-approved finished product.

• Ozempic: listed from $999 per month with limited supply. Ozempic is a registered trademark of Novo Nordisk A/S. Trademarks and product names belong to their respective owners. References to branded medications are for informational context only and do not represent affiliation, equivalence, or endorsement claims.

According to the company's published materials, the stated starting pricing is structured to include the medical consultation, prescription processing if issued, and free shipping, with no hidden fees noted. Final charges may vary based on the prescribed dose and the assigned pharmacy, and the company states that any variance is communicated by support staff before the order is processed. Buy Now Pay Later financing is noted as available at checkout. The program is structured as self-pay - insurance is not required and is not part of the program.

Prospective patients should verify current pricing, dose-specific costs, pharmacy assignment, subscription terms, auto-renewal conditions, and all checkout conditions directly with the brand before purchase.

View the current Trinity Meds offer summary

FDA Considerations for Compounded GLP-1 Medications in 2026

FDA considerations are central to any honest 2026 discussion of compounded GLP-1 medications, and this section should be read carefully by anyone evaluating a compounded GLP-1 program.

Trinity Meds' own published materials state that compounded GLP-1 medications are not FDA-approved or evaluated for safety, efficacy, or quality as finished products. The FDA has also warned consumers about risks associated with unapproved GLP-1 products, including dosing errors, adverse event reports, counterfeit or illegally marketed products, and medications sold outside appropriate medical oversight. As of early 2025, the FDA had received more than 455 adverse event reports linked to compounded semaglutide and more than 320 reports associated with compounded tirzepatide, many involving dosing errors from patients self-administering incorrect doses from multidose vials - some of which required hospitalization.

In addition, on April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list after finding no clinical need for outsourcing facilities to compound these drugs from bulk substances. FDA's proposal specifically concerns the 503B bulks list for outsourcing facilities, and readers should not assume it resolves every 503A, patient-specific, or state-law question related to compounded medications. The public comment period on this proposal closes June 29, 2026. After that date, the FDA will review submitted comments before making a final determination - meaning the regulatory status of compounded GLP-1 outsourcing facilities remains unresolved until at minimum that deadline passes. Separately, the FDA's resolution of the semaglutide shortage in February 2025 and the tirzepatide shortage in late 2024 already eliminated the primary basis that had permitted broad compounding of these drugs. The 503B proposal and the shortage resolutions operate through different legal mechanisms, and the regulatory landscape for compounded GLP-1 remains active as of the publication of this article.

For that reason, this advertorial does not present compounded GLP-1 medications as FDA-approved, generic versions of branded medications, or guaranteed substitutes for FDA-approved prescription products. Readers should discuss current FDA status, state-specific availability, pharmacy fulfillment, risks, benefits, dosing, and all alternatives with a licensed healthcare professional and the dispensing pharmacy before starting any treatment.

FDA Status Notice: Compounded semaglutide and compounded tirzepatide are not FDA-approved finished products and should not be presented as generic versions or equivalent substitutes for Ozempic, Wegovy, Mounjaro, or Zepbound. Readers should consult a licensed healthcare professional and review current FDA communications before using any compounded GLP-1 medication.

View the current Trinity Meds offer summary

Compounded GLP-1 vs. FDA-Approved Branded GLP-1 Medications

GLP-1 receptor agonists are a class of medications that act on pathways involved in appetite regulation, gastric emptying, and blood glucose control. FDA-approved GLP-1 medications have specific approved indications, dosing instructions, warnings, and prescribing information established through the FDA approval process - including clinical trial evaluation for safety and effectiveness.

Compounded GLP-1 medications are not FDA-approved finished products and are not the same as their branded counterparts. Per Trinity Meds' own published disclosures, compounded medications are produced by independent third-party pharmacies. The company's terms state that Trinity Meds makes no representations or warranties regarding the efficacy, safety, or outcomes of any medication provided through those pharmacies, and that adverse reactions or concerns should be directed to the prescribing provider or dispensing pharmacy.

The FDA has also noted that some compounded semaglutide preparations may contain salt forms - including semaglutide sodium and semaglutide acetate - which are different active ingredients than those used in the FDA-approved drugs. Patients should ask their dispensing pharmacy specifically about the form of the medication being compounded for their prescription.

Prospective patients considering compounded GLP-1 pathways should discuss the full distinction between compounded and FDA-approved options with a licensed healthcare professional before making any treatment decision.

How Trinity Meds Describes the Online Intake and Clinician Review Process

According to the company's published materials, Trinity Meds describes a three-step enrollment process:

Step 1 - Free online assessment. Per the company, a free intake questionnaire captures health history, current medications, weight, height, and goals. CareValidate Health has established exclusionary criteria, and the assessment is used to screen individuals who do not qualify - including those with documented contraindications such as a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Per the company's published terms, completing the assessment does not create a doctor-patient relationship.

Step 2 - Clinician review. Per the company's terms, a CareValidate Health clinician reviews the submitted intake information. In some cases, a prescription may be issued following that review; in others, a telehealth consultation is conducted before the prescribing decision. The terms state that the prescribing decision rests with the licensed clinician based on independent medical judgment. Payment does not guarantee a prescription.

Step 3 - Pharmacy fulfillment and delivery. If a prescription is issued, the company states it routes to one of the four named partner pharmacies for compounding and dispensing. Per the company, the typical enrollment-to-delivery timeline is approximately one and a half to three weeks, with free tracked shipping. The brand notes the medication received may look different from what is shown in marketing materials because compounded preparations are produced independently by each pharmacy.

Pharmacy Partners Named in Trinity Meds' Published Materials

According to the company's published FAQ, Trinity Meds names four pharmacy partners for prescription fulfillment. Each maintains publicly available contact information that patients can use to independently verify fulfillment details or ask questions about compounding practices:

• Belmar Pharmacy - 800-525-9473 | belmarpharmasolutions.com

• Strive Pharmacy - 855-405-5993 | strivepharmacy.com

• Epiq Scripts - 833-654-3553 | epiqscripts.com

• Casa Pharma Rx - 877-937-6868 | casapharmarx.com

Naming four specific dispensing pharmacies with direct contact information allows prospective patients to conduct independent due diligence on each pharmacy's state licensure, compounding practices, and any relevant regulatory history - before committing to the program.

Eligibility, Contraindications, and Why Prescription Approval Is Not Guaranteed

According to Trinity Meds' published materials, the following eligibility criteria apply to prospective patients:

• Users must be 18 years of age or older. The terms state that Trinity Meds does not provide services to minors under any circumstances.

• Published materials indicate that body composition consistent with FDA-recognized indications for GLP-1 weight management - generally a BMI in the obese range, or BMI in the overweight range with a related health condition - is typically required. The company notes that if BMI falls below 25 during the program, the clinician will reassess and may adjust dosing, shift to a maintenance protocol, or pause therapy based on health goals and individual risk factors.

• Absolute contraindications identified during intake - including a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 - will disqualify an applicant during screening.

Per published terms, the intake assessment is the first screening layer, but some applicants who pass intake may still be screened out by the clinician following consultation and full history review. According to the company, this reflects the clinician's exercise of independent medical judgment. The terms also state that clinicians may determine, on a case-by-case basis, that the services are not appropriate for a particular patient.

Regarding state availability: Trinity Meds' FAQ states the brand services all 50 states, while its published terms also indicate that service availability may depend on state-specific eligibility. Prospective patients should confirm current availability in their state directly with Trinity Meds before starting intake.

View the current Trinity Meds offer summary

Consumer Pathways Often Compared With GLP-1 Telehealth Programs

Patients researching GLP-1 weight management options in 2026 often compare several distinct pathways. Nothing in this section should be read as medical advice, insurance advice, legal advice, or a recommendation to choose any specific option. The appropriate pathway for any individual depends on medical history, diagnosis, insurance coverage, prescriber judgment, pharmacy availability, current FDA status, state law, and patient-specific risk factors.

Branded GLP-1 medication through a primary care provider. FDA-approved GLP-1 medications - including Wegovy and Zepbound for weight management, and Ozempic and Mounjaro for type 2 diabetes - are available through licensed prescribers. Patients with insurance coverage that includes these medications, or who may qualify for manufacturer assistance programs, should verify those options with their prescriber and insurer before considering other pathways.

Branded GLP-1 through insurance or manufacturer programs. Some patients may qualify for coverage or financial assistance that substantially reduces the cost of branded GLP-1 medications. This pathway should be explored before considering self-pay compounded alternatives, particularly given the current FDA regulatory environment around compounding.

Self-pay telehealth with clinician review and pharmacy fulfillment coordination. Programs such as Trinity Meds provide a self-pay pathway that may be considered by a licensed clinician as part of individual medical evaluation. These programs involve compounded medications that are not FDA-approved finished products. Eligibility is not guaranteed. The appropriateness of this pathway for any individual patient is a determination to be made by the prescribing clinician in light of that patient's medical history, current FDA guidance, and applicable state law.

Unsafe or illegal sourcing. The FDA has warned consumers specifically about GLP-1 products sold outside appropriate medical oversight, including counterfeit products, illegally marketed medications, and products sourced outside the regulated US pharmacy framework. No information in this article should be read as support for obtaining medication through unregulated channels.

Customer Support, Follow-Up, and Published Contact Options

According to the company's published materials, Trinity Meds states that program enrollment includes unlimited messaging access to clinical support staff and unlimited follow-up consultations with prescribing clinicians for the duration of the program. Customer support for billing, shipping, and administrative questions is available via dedicated email. The company's published materials also list direct contact information for each of the four dispensing pharmacy partners.

Testimonials: How to Read Brand-Published Customer Experiences

Trinity Meds' website includes customer testimonials discussing the intake process, clinician interactions, support experience, and self-reported weight-management experiences. These testimonials are published by the brand and should be read as individual customer reports - not as clinical evidence, typical outcomes, or guarantees of any kind.

Testimonials published by the brand are individual, self-reported experiences and are not clinical evidence, typical outcomes, or guarantees of weight loss, safety, suitability, or treatment response.

The brand's own disclosure states that claims and benefits on its website refer to self-reported data from customers on treatment plans that include compounded GLP-1 medications and consultations with licensed medical professionals, and that results vary based on adherence and clinician recommendations. A sample of published testimonials includes:

• "I have tried a few weight loss services before, but Trinity Meds feels much more organized and medically guided. The pricing is clear, nothing feels confusing, and they actually follow up with you." - Donnie Zimmerman, published on trinitymeds.com

• "Dr. Mansour was easy to talk to and answered all my questions. I feel great moving forward with this program." - Houston Cohea, published on trinitymeds.com

Individual results vary. Prescription medication may not be appropriate for every person, and all treatment decisions should be made by a licensed clinician based on medical history, contraindications, current medications, risk factors, and patient-specific needs.

Refunds, Billing, Auto-Renewal, Financing, and Subscription Terms

Trinity Meds' published terms state that medical consultation fees are not eligible for refund once a consultation has occurred. Prescription products cannot be returned for reuse or resale, and all prescription product sales are final. The terms also state that final charges may vary depending on the prescribed medication and the assigned pharmacy, with support communication if a variance occurs before the order is processed.

The company's financial consent terms include explicit auto-renewal language, stating that all programs are auto-renewing and that customers consent to automatic charges unless they explicitly request cancellation before their payment is processed. The terms state there are no refunds or exchanges.

Prospective patients should review all subscription, auto-renewal, cancellation, financing, and payment terms before completing checkout.

Who May Want to Discuss Trinity Meds With a Licensed Healthcare Professional

Based on Trinity Meds' published eligibility criteria and program disclosures, the following profile may be relevant for individuals considering whether to raise this program with their clinician: adults 18 or older who meet the published eligibility criteria, who have reviewed the compounded-versus-FDA-approved distinction as described in both Trinity Meds' own materials and current FDA communications, who have reviewed published refund and financial terms including auto-renewal conditions, who have already checked whether insurance or manufacturer assistance applies to branded GLP-1 options, and who are seeking a self-pay telehealth pathway with licensed clinician oversight.

Whether any individual is an appropriate candidate for compounded GLP-1 therapy - and whether that therapy remains available through a given pathway under current FDA guidance - is a determination to be made by a licensed clinician based on that individual's medical history, current medications, contraindications, and the most current regulatory guidance at the time of the consultation.

Who May Prefer FDA-Approved Branded Medication or a Different Care Pathway

Individuals who specifically want FDA-approved finished products should discuss branded GLP-1 options directly with their prescriber. Individuals whose insurance coverage would meaningfully reduce the cost of branded medications should verify that coverage before considering self-pay compounded alternatives. Individuals with contraindications identified during intake screening will not proceed past that stage. Individuals who are not comfortable with the regulatory distinctions associated with compounded medications - particularly in the context of the current FDA posture - should discuss all available options with a licensed healthcare professional before making any decision.

Final Consumer Checklist Before Enrolling

Before starting intake with any compounded GLP-1 telehealth program, the following items are worth verifying directly with the brand and with a licensed healthcare professional:

• Current pricing and dose-specific costs, which may vary from published starting pricing

• Auto-renewal, subscription, and cancellation terms before any payment is submitted

• Current FDA status of compounded GLP-1 medications and any applicable guidance updates, including the status of the April 30, 2026 proposed 503B exclusion

• State-specific availability and current program eligibility in your state

• Which pharmacy will fulfill the prescription and that pharmacy's current state licensure and compounding practices

• Whether the salt form of the compounded medication differs from the active ingredient in FDA-approved products, and what that means for your specific prescription

• Whether the prescribing clinician is licensed in your state and available for follow-up consultations

• Whether insurance, manufacturer assistance programs, or other pathways may apply to FDA-approved branded GLP-1 medications before committing to a self-pay compounded program

• Whether this program is appropriate given your individual medical history and risk factors - a determination for a licensed healthcare professional, not a website

View the current Trinity Meds offer summary

Contact Information

Customer Support Email: [email protected]
General Help Email: [email protected]
Corporate Address: Trinity Meds, Inc., 4575 Webb Bridge Road, Suite 4345, Alpharetta, GA 30005 USA
Mailing Address: 3333 W Kennedy Blvd, Suite 207, Tampa, FL 33609

Frequently Asked Questions About Trinity Meds GLP-1

Is Trinity Meds a pharmacy or a medical provider?
According to Trinity Meds' published terms, the platform does not directly provide medical or pharmacy services. Medical care is provided by CareValidate Health, an affiliated network of US-licensed clinicians. Medications are dispensed by independent third-party licensed pharmacies named in the company's published materials.

Are compounded semaglutide and tirzepatide the same as Ozempic, Wegovy, Mounjaro, or Zepbound?
No. Per Trinity Meds' own published disclosures, compounded GLP-1 medications are not FDA-approved finished products. They are not Wegovy, Ozempic, Mounjaro, or Zepbound, and they are not generic versions of those medications. They have not undergone FDA review for safety, effectiveness, or quality as finished products.

Does completing the intake guarantee a prescription?
No. According to the company's published terms, completing the online assessment does not create a doctor-patient relationship, and submitting payment does not guarantee a prescription. The prescribing decision is made by the CareValidate Health clinician after independent medical review.

What does the FDA's April 30, 2026 proposal mean for Trinity Meds patients?
FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list for outsourcing facilities. This proposal is currently in a public comment period through June 29, 2026, and is not yet final. The proposal concerns 503B outsourcing facilities specifically. Separately, the resolution of the semaglutide and tirzepatide shortages in 2024-2025 already eliminated the primary basis for broad compounding of these drugs. Prospective patients should review current FDA communications and discuss the current regulatory status with a licensed healthcare professional before enrolling.

Can I use insurance for Trinity Meds?
Per the company, Trinity Meds operates as a self-pay program. The affiliated medical providers are out-of-network. The program does not bill insurance. Buy Now Pay Later financing is available at checkout.

What is the Trinity Meds refund policy?
Per published terms, medical consultation fees are non-refundable once a consultation occurs. Prescription products cannot be returned, and all sales are final. The financial consent terms include auto-renewal language - patients must explicitly cancel before their payment processes to avoid renewal charges.

Does Trinity Meds service all 50 states?
The company's FAQ states it services all 50 states. Its published terms also indicate service availability may depend on state-specific eligibility. Prospective patients should confirm current availability directly with the brand before starting intake.

Is compounded semaglutide still available in 2026?
Compounded semaglutide remains available through some telehealth programs as of publication, but the regulatory environment has narrowed significantly. The FDA resolved the semaglutide shortage in February 2025, eliminating the primary basis for broad compounding. On April 30, 2026, the FDA also proposed excluding semaglutide from the 503B bulks list entirely. The public comment period on that proposal closes June 29, 2026. Prospective patients should verify current availability and regulatory status directly with any program and with a licensed healthcare professional before enrolling.

What does the June 29, 2026 FDA deadline mean for patients researching compounded GLP-1 programs?
June 29, 2026 is the close of the public comment period on the FDA's proposed rule to exclude semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facility bulks list. After that date, the FDA will review submitted comments and determine whether to finalize the exclusion. If finalized, outsourcing facilities would be prohibited from bulk compounding these drugs under any circumstances - including during future shortage events. The proposal does not directly affect 503A patient-specific compounding, though that pathway already lost its primary legal basis when the shortage declarations were resolved in 2024-2025. Patients should monitor FDA communications and discuss implications with a licensed healthcare professional.

Does the FDA's April 2026 proposal directly affect Trinity Meds?
Trinity Meds' published materials do not specify whether its dispensing pharmacy partners operate as 503A pharmacies, 503B outsourcing facilities, or both. The April 30, 2026 proposal directly targets 503B outsourcing facilities. The 503A pathway is governed separately, though it also lost its primary broad-compounding basis when the shortage declarations were resolved. Prospective patients should ask Trinity Meds and any assigned dispensing pharmacy directly about their current regulatory status and the basis on which any prescription would be compounded, given the evolving landscape as of May 2026.

How does Trinity Meds compare to branded GLP-1 programs after the FDA's 2026 regulatory changes?
Branded GLP-1 medications - Wegovy, Zepbound, Ozempic, Mounjaro - remain FDA-approved and commercially available. The 2026 regulatory changes specifically affect compounded versions. Trinity Meds' published starting pricing lists compounded semaglutide from $159 per month versus branded Ozempic listed at $999 per month on the company's own site - a significant self-pay cost difference. However, compounded medications are not FDA-approved finished products, are not generics, and have not undergone FDA review for safety, effectiveness, or quality. Patients whose insurance covers branded GLP-1 medications should verify that coverage first. The appropriate pathway is a decision for a licensed healthcare professional based on individual medical history, current FDA guidance, and the most current regulatory status at the time of consultation.

Additional Trinity Meds Coverage

For additional background on the Trinity Meds GLP-1 program, including earlier program overviews and pricing coverage, previously published resources are available here.

The publisher of this article has made every effort to ensure accuracy at the time of publication. We do not accept responsibility for errors, omissions, or outcomes resulting from use of the information provided. Readers are encouraged to verify all details directly with the official source before making a purchase decision.

Compounded semaglutide and compounded tirzepatide referenced throughout this article are not FDA-approved finished products and have not been individually reviewed by FDA for safety, effectiveness, or quality. Questions about whether a compounded medication may be prescribed in a particular circumstance should be addressed by the licensed clinician and dispensing pharmacy in light of patient-specific medical need, current FDA guidance, state law, and applicable compounding rules.

Compounded medications are produced by state-licensed pharmacies and FDA-registered outsourcing facilities, where applicable. Trinity Meds does not produce compounded medications; medications are dispensed by independent third-party licensed pharmacies. The decision to use compounded medications is made by a licensed prescribing clinician based on independent medical judgment. On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list. Readers should consult a licensed healthcare professional and review current FDA communications for up-to-date guidance.

Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective manufacturers. References to branded GLP-1 medications are for informational context only and do not represent endorsement, affiliation, or equivalence claims. The publisher is not affiliated with and does not claim endorsement by Novo Nordisk, Eli Lilly, or any branded GLP-1 manufacturer.

All claims, benefits, and customer-reported outcomes referenced in this article reflect self-reported data from Trinity Meds program patients as published on the brand's website. Individual results vary and are not typical. Results depend on individual starting weight, program adherence, clinician recommendations, dietary patterns, physical activity, and individual physiological response.

Completing the Trinity Meds online assessment does not, by itself, create a doctor-patient relationship. The doctor-patient relationship is established only when a CareValidate Health clinician reviews the intake and completes a telehealth evaluation. The decision to issue a prescription rests with the licensed clinician based on independent medical judgment. A prescription is not guaranteed by completing intake or submitting payment.

This site is an advertisement for services and not any specific medication. Payment does not guarantee a prescription. The publisher is not providing medical, legal, regulatory, or pharmacy advice. Readers should verify current FDA status, pricing, pharmacy assignment, availability, and all program terms directly with the brand and with relevant healthcare professionals before making any enrollment decision.

This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a licensed healthcare professional with any questions regarding your health or medical conditions, and before commencing or discontinuing any course of treatment, drug, or medication. If you believe you are experiencing a medical emergency, dial 911 or contact your local emergency services immediately.

SOURCE: Trinity Meds

Source: Trinity Meds